<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vincristine (conventional): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vincristine (conventional): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Vincristine (conventional): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10045" href="/d/html/10045.html" rel="external">see "Vincristine (conventional): Drug information"</a> and <a class="drug drug_patient" data-topicid="11143" href="/d/html/11143.html" rel="external">see "Vincristine (conventional): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708854"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Experienced provider:</span>
<div class="collapsible-wrap">
<p style="text-indent:-4em;margin-left:4em;">Vincristine should be administered by individuals experienced in the administration of vincristine.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Extravasation:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">It is extremely important that the IV needle or catheter be properly positioned before any vincristine is injected. Leakage into surrounding tissue during IV administration may cause considerable irritation. If extravasation occurs, discontinue the injection immediately and then introduce any remaining portion of the dose into another vein. Local injection of hyaluronidase and the application of moderate heat to the area of leakage will help disperse the drug and are thought to minimize discomfort and the possibility of cellulitis.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">For IV use only:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">For IV use only. Fatal if given by other routes. See "Additional Information/Pharmacotherapy Pearls" for treatment of patients given (inadvertent) intrathecal administration of vincristine.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F234194"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Vincasar PFS [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1050610"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Antimicrotubular</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Mitotic Inhibitor</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Vinca Alkaloid</span></li></ul></div>
<div class="block don drugH1Div" id="F53462620"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol. In pediatric patients, dosing may be based on either BSA (mg/m<sup>2</sup>) or weight (mg/kg); use extra precaution to verify dosing parameters during calculations.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2f930c6e-27e7-4ef2-b112-96407f58305c">Neuroblastoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma:</b> Limited data available: CE-CAdO regimen:</p>
<p style="text-indent:-2em;margin-left:4em;">Newborns: IV: 0.035 mg/<b>kg/dose </b> on day 1, then every 21 days for 2 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9649151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9649151'])">Ref</a></span>) or on days 1 and 5 for 2 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172879'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">Older neonates: IV: 0.05 mg/<b>kg/dose</b> on days 1 and 5 for 2 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172879'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F234221"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Doses are almost always capped at a maximum of 2 mg/dose/week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20564411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20564411'])">Ref</a></span>). Dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol. In pediatric patients, dosing may be based on either BSA (mg/m<sup>2</sup>) or weight (mg/kg); use extra precaution to verify dosing parameters during calculations. For infants and children &lt;10 kg, dosing is typically reduced (eg, 30% reduction); refer to specific protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172879'])">Ref</a></span>). The World Health Organization (WHO) and the Institute for Safe Medication Practices (ISMP) strongly recommend dispensing vincristine in a minibag (<b>NOT</b> in a syringe) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="75077c6b-94bd-4dd6-9bba-895ed97d27ed">Acute lymphocytic leukemia of infancy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphocytic leukemia (ALL) of infancy:</b> Limited data available: Infants &lt;1 year of age at diagnosis: IV: 1.5 mg/m<sup>2</sup>/dose; maximum dose: 2 mg/dose; reported frequency variable but not more frequently than weekly.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pieters 2007</i>: Interfant-99 protocol: Administer on the following days: Induction phase: Days 8, 15, 22, and 29 (in combination with prednisone, dexamethasone, cytarabine, daunorubicin, l-asparaginase, and CNS intrathecal prophylaxis); Reinduction: Days 1, 8, 15, and 22 (in combination with dexamethasone, 6-thioguanine, daunorubicin, cytarabine, cyclophosphamide, and CNS intrathecal prophylaxis).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e2608d05-9734-4abb-8c04-42e807e5aa80">Acute lymphocytic leukemia, standard risk and high risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphocytic leukemia (ALL), standard risk and high risk:</b> Limited data available: Children and Adolescents: IV: 1.5 mg/m<sup>2</sup>/dose; maximum dose: 2 mg/dose; reported frequency variable but not more frequent than weekly:</p>
<p style="text-indent:-2em;margin-left:4em;">Standard risk:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Avramis 2002:</i> Administer dose on the following days: Induction phase: Days 0, 7, 14, and 21; Consolidation phase: Days 0, 28, and 56; Interim maintenance phases: Days 0 and 28; Delayed intensification phase: Days 0, 7, and 14; Maintenance phase: Every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Bostrom 2003:</i> Administer dose on the following days: Induction phase: Days 0, 7, 14, and 21; Consolidation phase: Days 0, 28, and 56; Delayed intensification phase: Days 0, 7, and 14; Maintenance phase: Days 0, 28, and 56.</p>
<p style="text-indent:-2em;margin-left:4em;">High risk: <i>Larsen 2016</i>: Administer on the following days: Induction phase: Days 1, 8, 15, and 22; Extended Induction: Days 1 and 8; Consolidation: Days 15, 22, 43, and 50; Interim Maintenance 1: Days 1, 15, 29, and 42; Interim Maintenance 2: Days 1, 11, 21, 31, and 41; Delayed Intensification 1: Days 1, 8, 15, 43, and 50; Delayed Intensification 2: Days 1, 8, 15, 43, and 50; Maintenance phase: Every 4 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aee220af-0844-4780-b143-cde0d52e0c13">Ewing sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ewing sarcoma:</b> Limited data available: Children and Adolescents: Dose and frequency regimens variable:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Grier 2003:</i> IV: 2 mg/m<sup>2</sup>/dose on day 1 of a 21-day cycle, administer either every cycle or during odd-numbered cycles (VDC/IE regimen); maximum dose: 2 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Kolb 2003:</i> IV: 0.67 mg/m<sup>2</sup>/<b>day</b> as a continuous IV infusion on days 1, 2, and 3; total dose for cycle: 2 mg/m<sup>2</sup>/<b>cycle</b> (maximum dose/cycle: 2 mg/dose/cycle) during cycles 1, 2, 3, and 6.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ce17d3e0-5a62-4c43-92d4-7e6e951d1d27">Hepatoblastoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatoblastoma:</b> Limited data available: Infants, Children, and Adolescents: C5V Regimen: IV: 1.5 mg/m<sup>2</sup>/dose on Day 2 of a 3-week treatment cycle for 4 cycles (in combination with 5-fluorouracil and cisplatin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10894865']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10894865'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27e021a7-5ca5-4246-a732-eef1337a6f18">Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">AV-PC (low-risk regimen): Children and Adolescents: IV: 1.4 mg/m<sup>2</sup>/dose (maximum dose: 2.8 mg/dose) on Day 1 and 8 of a 21-day treatment cycle for 3 cycles (in combination with doxorubicin, prednisone, and cyclophosphamide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27185849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27185849'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">ABVE-PC (high-risk and intermediate regimens): Children and Adolescents: IV: 1.4 mg/m<sup>2</sup>/dose (maximum dose: 2.8 mg/dose) on Day 1 and 8 of a 21-day treatment cycle for 3 to 5 cycles in combination with doxorubicin, bleomycin, etoposide, cyclophosphamide, and prednisone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25311218','lexi-content-ref-19584400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25311218','lexi-content-ref-19584400'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Bv-AVE-PC (high-risk regimen): Children ≥2 years and Adolescents: IV: 1.4 mg/m<sup>2</sup>/dose (maximum dose: 2.8 mg/dose) on Day 8 of a 21-day treatment cycle for up to 5 cycles in combination with brentuximab, doxorubicin, etoposide, cyclophosphamide, and prednisone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36322844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36322844'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">BEACOPP regimen (high-risk regimen): Children and Adolescents: IV: 2 mg/m<sup>2</sup>/dose on day 7 of a 21-day treatment cycle for 4 cycles (in combination with bleomycin, etoposide, doxorubicin, cyclophosphamide, procarbazine, and prednisone); maximum dose: 2 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12078889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12078889'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7504889f-ccbb-425d-abaf-13ec7be68057">Low-grade glioma, CNS tumor</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Low-grade glioma, CNS tumor (low-grade ependymoma, infantile desmoplastic astrocytoma, etc)</b>: Limited data available: Children &lt;10 years: IV: 1.5 mg/m<sup>2</sup>/dose; maximum dose: 2 mg/dose; reported combination chemotherapy and frequency variable but not more frequent than weekly:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ater 2012:</i> CV regimen: Administer on the following days: Induction phase: Days 0, 7, 14, 21, 28, 35, 42, 49, 56, and 63 of an 84-day cycle (in combination with carboplatin); Maintenance phase: Day 0, 7, and 14 of a 42-day cycle for 8 cycles (in combination with carboplatin).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ater 2012: </i>TPCV regimen: Administer on days 14 and 28 of a 42-day cycle (in combination with thioguanine, procarbazine, and lomustine) for a total of 8 cycles.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3dfdb412-f65b-4afc-bb85-aa3a69a650da">Medulloblastoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Medulloblastoma:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Average-risk regimen: Children ≥3 years and Adolescents: IV: 1.5 mg/m<sup>2</sup>/dose (maximum dose: 2 mg/dose) once weekly during radiation therapy for up to 8 doses followed by 1.5 mg/m<sup>2</sup>/dose (maximum dose: 2 mg/dose) on days 1, 7, and 14 per cycle (in combination with cisplatin and either lomustine or cyclophosphamide) for 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16943538']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16943538'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">High risk: Head Start II Protocol: Children &lt;10 years: IV: 0.05 mg/<b>kg</b>/dose on Days 1, 8, and 15 of a 21-day cycle in cycles 1 to 3 only (9 total doses in combination with cisplatin, etoposide, cyclophosphamide, methotrexate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15611503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15611503'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2f930c6e-27e7-4ef2-b112-96407f58305c">Neuroblastoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants:</p>
<p style="text-indent:-2em;margin-left:6em;">Low-dose cyclophosphamide-vincristine regimen: IV: 0.05 mg/<b>kg</b>/dose vincristine on day 1, and repeat in 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14583756']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14583756'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CAdO regimen: IV: 0.05 mg/<b>kg</b>/dose on day 1 and 5 and repeated in 21 days (in combination with cyclophosphamide and doxorubicin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14583756','lexi-content-ref-21172879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14583756','lexi-content-ref-21172879'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">High risk: Induction therapy: IV: 1.5 mg/m<sup>2</sup>/dose Day 1 in combination with doxorubicin and cyclophosphamide for cycles 2 and 5 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23334272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23334272'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Refractory: HD-CTV regimen: IV: 0.067 mg/<b>kg</b>/dose or 2 mg/m<sup>2</sup>/dose, whichever is lower; maximum dose: 2 mg/dose on day 1 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20564411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20564411'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6d4c856e-dedc-4b57-9bc3-4eb783e31618">Non-Hodgkin lymphomas</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphomas: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Burkitt lymphoma, Diffuse large B-cell lymphoma and B-cell ALL</i>:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cairo 2007, Goldman 2013, Goldman 2014:</i> Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Reduction (COP regimen): IV: 1 mg/m<sup>2</sup>/dose; maximum dose: 2 mg/dose on Day 1 (in combination with cyclophosphamide, prednisone, and intrathecal methotrexate).</p>
<p style="text-indent:-2em;margin-left:8em;">Induction 1 and 2 (COPADM regimen): IV: 2 mg/m<sup>2</sup>/dose; maximum dose: 2 mg/dose on Day 1 (in combination with cyclophosphamide, prednisone, doxorubicin, methotrexate, and intrathecal methotrexate).</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance 1 (COPAM regimen) and 3 (COPA regimen): IV: 2 mg/m<sup>2</sup>/dose; maximum dose: 2 mg/dose on Day 1 (in combination with cyclophosphamide, prednisone, doxorubicin, and methotrexate [maintenance 1 only]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Reiter 1999:</i> Children and Adolescents: IV: 1.5 mg/m<sup>2</sup>/dose; maximum dose: 2 mg/dose; administer dose on day 1 of cycle AA (in combination with dexamethasone, ifosfamide, methotrexate, cytarabine, etoposide, and CNS prophylaxis) and on day 1 of cycle BB (in combination with dexamethasone, cyclophosphamide, methotrexate, doxorubicin, and CNS prophylaxis).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Primary mediastinal B-cell Lymphoma (PMBCL):</b></i> Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">DA-EPOCH-R regimen: Children ≥9 years and Adolescents: IV: 0.4 mg/m<sup>2</sup>/<b>day </b>as a continuous infusion over 96 hours on days 1 to 4 (in combination with rituximab, doxorubicin, etoposide, cyclophosphamide, prednisone, and filgrastim); no maximum dose. Doses for subsequent cycles are based on neutrophil and platelet counts; repeat cycle every 3 weeks for a total of 6 to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23574119','lexi-content-ref-29082519','lexi-content-ref-23863060']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23574119','lexi-content-ref-29082519','lexi-content-ref-23863060'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="31e6cee0-3b53-4b61-b4ee-8c7e85d9d0bb">Retinoblastoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Retinoblastoma:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children ≤36 months: IV: 0.05 mg/<b>kg</b>/dose (maximum dose: 2 mg/dose); reported frequency variable but not more frequent than weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Rodriguez-Galindo 2003:</i> Administer dose on day 1 every 21 days in combination with carboplatin for 8 cycles.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Friedman 2000:</i> Administer dose day 0 every 28 days in combination with carboplatin and etoposide for 6 cycles.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;36 months: IV: 1.5 mg/m<sup>2</sup> (maximum dose: 2 mg/dose) on day 0 every 28 days in combination with carboplatin and etoposide for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10623688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10623688'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5504217-4a06-41a9-8929-da042d28bae3">Rhabdomyosarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhabdomyosarcoma:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21357783','lexi-content-ref-21298768','lexi-content-ref-25267746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21357783','lexi-content-ref-21298768','lexi-content-ref-25267746'])">Ref</a></span>); reported frequency variable but not more frequent than weekly: Duration of therapy depends on risk status; VA (in combination with dactinomycin) or VAC regimen (in combination with dactinomycin and cyclophosphamide):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: IV: 0.025 mg/<b>kg</b>/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 to &lt;3 years: IV: 0.05 mg/<b>kg</b>/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥3 years and Adolescents: IV: 1.5 mg/m<sup>2</sup>/dose (maximum dose: 2 mg/dose).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e8cead17-5b33-4326-9157-7fee0fdfa8f5">Wilms tumor</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Wilms tumor:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16547940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16547940'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children weighing ≤30 kg: IV: 0.05 mg/<b>kg</b>/dose (maximum dose: 2 mg/dose) weeks 1, 2, 4, 5, 6, 7, 8, 10, and 11, followed by 0.067 mg/<b>kg</b>/dose (maximum dose: 2 mg/dose) weeks 12, 13, 18, and 24 (in combination with doxorubicin, cyclophosphamide, mesna, etoposide, and filgrastim).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents weighing &gt;30 kg: IV: 1.5 mg/m<sup>2</sup>/dose (maximum dose: 2 mg) weeks 1, 2, 4, 5, 6, 7, 8, 10, and 11, followed by 2 mg/m<sup>2</sup>/dose (maximum dose: 2 mg) weeks 12, 13, 18, and 24 (in combination with doxorubicin, cyclophosphamide, mesna, etoposide, and filgrastim).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> Refer to specific protocols for detail for guidance.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hodgkin lymphoma, classic; high-risk: </b>Children ≥2 years and Adolescents: IV: When used as part of a Bv-AVE-PC regimen with brentuximab, doxorubicin, etoposide, prednisone, and cyclophosphamide along with filgrastim (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36322844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36322844'])">Ref</a></span>). <b>Note:</b> Adjustment to the brentuximab dose may be necessary in some instances; refer to Brentuximab monograph for details.</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Vincristine Dosage Adjustment for Peripheral Neuropathy Toxicity in Pediatric Patients (Combination Therapy With Brentuximab)<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><tfoot valign="top">
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">
<sup>a</sup> Adcetris prescribing information 2022.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">
<i>Peripheral neuropathy: Grade 2</i></p></td>
<td align="left">
<p style="text-indent:0em;">Reduce vincristine dose per protocol; if neuropathy improves to ≤ grade 1 by day 8 of next cycle, then resume vincristine at full dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<i>Peripheral neuropathy: Grade 3 or 4</i></p></td>
<td align="left">
<p style="text-indent:0em;">Discontinue vincristine.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51220291"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations; consult individual protocols; based on experience in adult patients, dosing adjustment may not be necessary.</p></div>
<div class="block dohp drugH1Div" id="F51193273"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">All patients: The manufacturer's labeling recommends the following adjustment: Serum bilirubin &gt;3 mg/dL: Administer 50% of normal dose.</p>
<p style="text-indent:-2em;margin-left:4em;">The following adjustments have also been recommended:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Floyd 2006:</i> Serum bilirubin 1.5 to 3 mg/dL or transaminases 2 to 3 times ULN or alkaline phosphatase increased: Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Superfin 2007:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Serum bilirubin 1.5 to 3 mg/dL: Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Serum bilirubin &gt;3 mg/dL: Avoid use.</p></div>
<div class="block doa drugH1Div" id="F234199"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10045" href="/d/html/10045.html" rel="external">see "Vincristine (conventional): Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dispense vincristine in a minibag or other flexible plastic container (<b>NOT </b>in a syringe) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.1'])">Ref</a></span>). Some doses may be capped at a maximum of 2 mg/dose; refer to protocol. Dosing and frequency may vary by protocol and/or treatment phase. Patients receiving vincristine should be on a prophylactic bowel management regimen to prevent constipation.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b0a6d83-a7ac-4bd2-8948-9f49f264da2d">Acute lymphocytic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphocytic leukemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CALGB 10403 regimen: Patients &lt;40 years of age: <b>IV:</b> Induction phase: 1.5 mg/m<sup>2</sup> (maximum: 2 mg) on days 1, 8, 15, and 22; Extended remission induction phase (if required): 1.5 mg/m<sup>2</sup> (maximum: 2 mg) on day 1 and 8; Remission consolidation phase: 1.5 mg/m<sup>2</sup> (maximum: 2 mg) on days 15, 22, 43, and 50; Delayed intensification phase: 1.5 mg/m<sup>2</sup> (maximum: 2 mg) on days 1, 8, 43, and 50; Maintenance phase: 1.5 mg/m<sup>2</sup> (maximum: 2 mg) on days 1, 29, and 57 of a 12-week cycle; continue maintenance phase until 2 years (females) or 3 years (males) from start of interim maintenance; phases are part of combination chemotherapy; refer to protocol for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30658992']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30658992'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">DFCI Consortium regimen: Patients ≤50 years of age: <b>IV:</b> Induction phase: 2 mg on days 1, 8, 15, and 22 (4-week treatment cycle); CNS therapy phase: 2 mg for one dose (3-week treatment cycle); Intensification phase: 2 mg on day 1 (3-week cycle; continue for 30 weeks); Continuation phase: 2 mg on day 1 (3-week cycle; continue for 74 weeks); phases are part of combination chemotherapy; refer to protocol for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25079173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25079173'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Hyper-CVAD regimen: <b>IV: </b>2 mg on days 4 and 11 during odd-numbered cycles (cycles 1, 3, 5, 7 [in combination with cyclophosphamide, mesna, doxorubicin, and dexamethasone]) of an 8-cycle phase, followed by maintenance treatment (if needed) of 2 mg once monthly for 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15481055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15481055'])">Ref</a></span>), plus a tyrosine kinase inhibitor (for Philadelphia chromosome-positive disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20466853','lexi-content-ref-14551133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20466853','lexi-content-ref-14551133'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CALBG 8811 regimen: <b>IV: </b>Induction phase: 2 mg on days 1, 8, 15, and 22 (4-week treatment cycle); Early intensification phase: 2 mg on days 15 and 22 (4-week treatment cycle, repeat once); Late intensification phase: 2 mg on days 1, 8, and 15 (8-week treatment cycle); Maintenance phase: 2 mg on day 1 every 4 weeks until 24 months from diagnosis; phases are part of combination chemotherapy; refer to protocol for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7718875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7718875'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">GRAALL 2003 regimen: Patients &lt;60 years of age: <b>IV: </b>Induction phase: 2 mg on days 1, 8, 15, and 22; Consolidation phase: 2 mg on day 15 of consolidation blocks 2, 5, and 8; Late intensification phase: 2 mg on days 1, 8, and 15; Maintenance phase: 2 mg on day 1 every month for 12 months; phases are part of combination chemotherapy; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19124805']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19124805'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">GRAALL 2005 regimen: Patients &lt;60 years of age: <b>IV:</b> Induction phase: 2 mg on days 1, 8, 15, and 22; Interphase-1: 2 mg on day 1; First, second, and third consolidation phases (block 2, block 5, and block 8, respectively): 2 mg on day 15; Late intensification phase (if complete response after first course): 2 mg on days 1, 8, 15, and 22; Maintenance phase: 2 mg on day 1 monthly for 12 months; phases are part of combination chemotherapy; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29863974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29863974'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">MRC UKALL XII/ECOG E2993: Patients &lt;60 years of age: <b>IV: </b>Induction (phase 1): 1.4 mg/m<sup>2</sup> on days 1, 8, 15, and 22; Consolidation phase (cycle 1): 1.4 mg/m<sup>2</sup> on days 1, 8, 15, and 22; Maintenance phase: 1.4 mg/m<sup>2</sup> once every 3 months; continue maintenance for 2.5 years from the start of intensification; phases are part of combination chemotherapy; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16105981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16105981'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Philadelphia chromosome-positive acute lymphoblastic lymphoma:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Kim 2015:</i>
<b>IV: </b>2 mg on days 1 and 8 of induction and consolidation A cycles (in combination with daunorubicin, prednisolone, cytarabine, etoposide, methotrexate, leucovorin, and nilotinib); refer to protocol for further information.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Rousselot 2016:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Patients ≥55 to ≤70 years of age: Induction: <b>IV: </b>2 mg once weekly for 4 weeks (in combination with dexamethasone and dasatinib); refer to protocol for further information.</p>
<p style="text-indent:-2em;margin-left:8em;">Patients &gt;70 years of age: Induction: <b>IV: </b>1 mg once weekly for 4 weeks (in combination with dexamethasone and dasatinib); refer to protocol for further information.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5c09b86d-f2a5-4aba-94b0-db9df04ebdf3">Central nervous system tumors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Central nervous system tumors (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Anaplastic oligodendroglioma/astrocytomas, low-grade gliomas</i>: PCV regimen (in combination with procarbazine, lomustine, and radiation therapy): <b>IV: </b>1.4 mg/m<sup>2</sup> (some protocols cap the vincristine dose at 2 mg; refer to protocols for details) on days 8 and 29 of a 6- to 8-week treatment cycle for 4 to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27050206','lexi-content-ref-16782910','lexi-content-ref-23071247','lexi-content-ref-22851558','lexi-content-ref-23071237','lexi-content-ref-16782911']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27050206','lexi-content-ref-16782910','lexi-content-ref-23071247','lexi-content-ref-22851558','lexi-content-ref-23071237','lexi-content-ref-16782911'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Glioblastoma, recurrent: </i>PCV regimen (in combination with procarbazine and lomustine): <b>IV:</b> 1.4 mg/m<sup>2</sup> (maximum: 2 mg) on days 8 and 29 of a 6-week cycle for 7 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11051233']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11051233'])">Ref</a></span>) or 1.5 mg/m<sup>2</sup> (maximum: 2 mg) on day 1 of a 6-week cycle for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20855843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20855843'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Medulloblastoma: </i>Adults ≤21 years of age: <b>IV: </b>1.5 mg/m<sup>2</sup> (maximum dose: 2 mg) weekly for a maximum of 8 doses (in combination with radiation, cisplatin, and either lomustine or cyclophosphamide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16943538']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16943538'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33717756-ede5-4bca-9eda-b506ad2cfa5d">Chronic lymphocytic leukemia/small lymphocytic leukemia, with Richter transformation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic lymphocytic leukemia/small lymphocytic leukemia, with Richter transformation (off-label use):</b>
<b>IV:</b> 2 mg (flat dose) days 4 and 11 of courses 1, 3, 5, and 7 (in combination with cyclophosphamide, mesna, doxorubicin, and dexamethasone [± rituximab]) and alternates with even courses 2, 4, 6, and 8 (methotrexate, leucovorin, and cytarabine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16502413','lexi-content-ref-12655528']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16502413','lexi-content-ref-12655528'])">Ref</a></span>) <b>or</b> 1.4 mg/m<sup>2</sup> (maximum dose: 2 mg) on day 1 of a 21-day treatment cycle (in combination with cyclophosphamide, doxorubicin, and prednisone [± rituximab]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11807147','lexi-content-ref-16710033']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11807147','lexi-content-ref-16710033'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aee220af-0844-4780-b143-cde0d52e0c13">Ewing sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ewing sarcoma (off-label use):</b> VDC/IE regimen: VDC: <b>IV: </b>2 mg/m<sup>2</sup> (maximum dose: 2 mg) on day 1 of a 21-day treatment cycle (in combination with doxorubicin and cyclophosphamide), alternates with IE (ifosfamide and etoposide) for a total of 17 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12594313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12594313'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="feb4894f-2d13-4fa6-9687-d81a4d1064dc">Gestational trophoblastic tumors, high-risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gestational trophoblastic tumors, high-risk (off-label use):</b> EMA/CO regimen: <b>IV:</b> 1 mg/m<sup>2</sup> on day 8 of a 2-week treatment cycle (in combination with etoposide, methotrexate, leucovorin, dactinomycin, and cyclophosphamide), continue for at least 2 treatment cycles after a normal hCG level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14675675','lexi-content-ref-17086804']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14675675','lexi-content-ref-17086804'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27e021a7-5ca5-4246-a732-eef1337a6f18">Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma:</b></p>
<p style="text-indent:-2em;margin-left:4em;">BEACOPP (standard or escalated) regimen: <b>IV: </b>1.4 mg/m<sup>2</sup> (maximum dose: 2 mg) on day 8 of a 21-day treatment cycle (in combination with bleomycin, etoposide, doxorubicin, cyclophosphamide, procarbazine, and prednisone) for 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12802024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12802024'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Stanford-V regimen: <b>IV: </b>1.4 mg/m<sup>2</sup> (maximum dose: 2 mg) in weeks 2, 4, 6, 8, 10, and 12 (in combination with mechlorethamine, vinblastine, bleomycin, doxorubicin, etoposide, and prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11821442','lexi-content-ref-10694546']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11821442','lexi-content-ref-10694546'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6402e3f0-529b-4535-9c41-7e49e14d9e66">Merkel cell carcinoma, advanced or recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Merkel cell carcinoma, advanced or recurrent (off-label use; based on limited data):</b> CAV regimen: <b>IV: </b>2 mg on day 1 every 21 days (in combination with cyclophosphamide and doxorubicin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9307187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9307187'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a4f575b1-9ab5-4ea5-b16e-1724f4fcbc62">Multiple myeloma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">DVD regimen: <b>IV: </b>1.4 mg/m<sup>2</sup> (maximum dose: 2 mg) on day 1 of a 28-day treatment cycle (in combination with pegylated doxorubicin and dexamethasone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16404741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16404741'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">VAD regimen: <b>IV: </b>0.4 mg/day continuous infusion for 4 days (over 96 hours) (total 1.6 mg/cycle) of a 28-day treatment cycle (in combination with conventional doxorubicin and dexamethasone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16404741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16404741'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6d4c856e-dedc-4b57-9bc3-4eb783e31618">Non-Hodgkin lymphomas</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphomas:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Burkitt lymphoma:</i></p>
<p style="text-indent:-2em;margin-left:6em;">CALGB 10002 regimen (cycles 2 through 7): <b>IV: </b>2 mg on day 1 every 3 weeks (in combination with cyclophosphamide, prednisone, ifosfamide, dexamethasone, methotrexate, leucovorin, cytarabine, etoposide, rituximab, doxorubicin, intrathecal therapy, and filgrastim); refer to protocol for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24428673']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24428673'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CODOX-M/IVAC: Cycles 1 and 3 (CODOX-M): <b>IV: </b>1.5 mg/m<sup>2</sup> (no maximum dose) days 1 and 8 of cycle 1 and days 1, 8, and 15 of cycle 3 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8622041']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8622041'])">Ref</a></span>) <b>or</b> 1.5 mg/m<sup>2</sup> (maximum dose: 2 mg) days 1 and 8 of cycles 1 and 3 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18612102','lexi-content-ref-12181251']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18612102','lexi-content-ref-12181251'])">Ref</a></span>); CODOX-M is in combination with cyclophosphamide, doxorubicin, methotrexate, and CNS prophylaxis and alternates with IVAC (etoposide, ifosfamide, mesna, cytarabine, and CNS prophylaxis) for a total of 4 cycles.</p>
<p style="text-indent:-2em;margin-left:6em;">R-Hyper-CVAD: <b>IV: </b>2 mg (flat dose) days 4 and 11 of courses 1, 3, 5, and 7 (in combination with rituximab, cyclophosphamide, doxorubicin, and dexamethasone) and alternates with even courses 2, 4, 6, and 8 (rituximab, methotrexate and cytarabine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16502413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16502413'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Diffuse large B-cell lymphoma:</i></p>
<p style="text-indent:-2em;margin-left:6em;">CHOP/R-CHOP regimen: <b>IV: </b>1.4 mg/m<sup>2</sup> (maximum dose: 2 mg) on day 1 of a 21-day treatment cycle for 8 cycles (in combination with cyclophosphamide, doxorubicin, and prednisone [± rituximab]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11807147']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11807147'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Dose-adjusted EPOCH/EPOCH-R regimen: <b>IV: </b>0.4 mg/m<sup>2</sup>/day continuous infusion for 4 days (over 96 hours) (total 1.6 mg/m<sup>2</sup>/cycle; dose not usually capped) of a 21-day treatment cycle (in combination with etoposide, prednisone, cyclophosphamide, and doxorubicin, ± rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17233819','lexi-content-ref-11929754']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17233819','lexi-content-ref-11929754'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">R-CEOP regimen: <b>IV: </b>1.4 mg/m<sup>2</sup> (maximum dose: 2 mg) on day 1 of a 21-day treatment cycle for 3 to 6 cycles (in combination with rituximab, cyclophosphamide, etoposide, and prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moccia.2009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moccia.2009'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Follicular lymphoma:</i></p>
<p style="text-indent:-2em;margin-left:6em;">CVP regimen: <b>IV: </b>1.4 mg/m<sup>2</sup> (maximum dose: 2 mg) on day 1 of a 21-day treatment cycle (in combination with cyclophosphamide and prednisone [± rituximab or obinutuzumab]) for 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28976863','lexi-content-ref-15494430']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28976863','lexi-content-ref-15494430'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">R-CHOP regimen: <b>IV: </b>1.4 mg/m<sup>2</sup> (maximum dose: 2 mg) on day 1 of a 21-day treatment cycle for 6 to 8 cycles (in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16123223']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16123223'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Peripheral T-cell lymphoma: </i></p>
<p style="text-indent:-2em;margin-left:6em;">CHOEP regimen: <b>IV: </b>2 mg on day 1 of a 21-day treatment cycle (in combination with cyclophosphamide, doxorubicin, etoposide, and prednisone) for 6 to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14982884','lexi-content-ref-20660290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14982884','lexi-content-ref-20660290'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CHOP regimen: <b>IV: </b>1.4 mg/m<sup>2</sup> (maximum dose: 2 mg) on day 1 of a 21-day treatment cycle (in combination with cyclophosphamide, doxorubicin, and prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20660290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20660290'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Primary mediastinal B-cell lymphoma: </i> DA-EPOCH-R regimen<i>:</i>
<b>IV: </b>0.4 mg/m<sup>2</sup>/day (no cap) as a continuous infusion on days 1 to 4 (over 96 hours) dose-adjusted for subsequent cycles based on neutrophil and platelet counts during nadir (in combination with etoposide, prednisone, cyclophosphamide, doxorubicin, rituximab, and filgrastim); repeat cycle every 3 weeks for a total of 6 to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23574119']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23574119'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7322d635-ec03-41b2-b458-e6daed980825">Ovarian cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer (off-label use):</b> VAC regimen: <b>IV: </b>1.5 mg/m<sup>2</sup> (maximum dose: 2 mg) once weekly for 8 to 12 weeks (in combination with dactinomycin and cyclophosphamide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2988740']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2988740'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="60a3049d-932f-4cb6-8b42-d79eefa7ea93">Pheochromocytoma, malignant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pheochromocytoma, malignant (off-label use; based on limited data): IV:</b> 1.4 mg/m<sup>2</sup> on day 1 every 3 or 4 weeks (in combination with cyclophosphamide and dacarbazine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18780317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18780317'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="742c866d-624d-41cf-a1cb-742554aedc03">Primary CNS lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary CNS lymphoma (off-label use):</b> R-MPV regimen: Induction: <b>IV: </b>1.4 mg/m<sup>2</sup> (maximum dose: 2.8 mg or per standard of practice) on day 1 or day 2 of a 14-day cycle for 5 to 7 cycles (in combination with rituximab, high-dose methotrexate, leucovorin, and procarbazine), followed by reduced-dose whole brain radiotherapy and cytarabine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24101038','lexi-content-ref-17947720']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24101038','lexi-content-ref-17947720'])">Ref</a></span>) or autologous stem cell transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25568347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25568347'])">Ref</a></span>). Two additional cycles of R-MPV may be administered to patients with partial response after initial induction chemotherapy; refer to protocols for details.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5504217-4a06-41a9-8929-da042d28bae3">Rhabdomyosarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhabdomyosarcoma: </b></p>
<p style="text-indent:-2em;margin-left:4em;">VAC regimen: Patients &lt;50 years: <b>IV: </b>1.5 mg/m<sup>2</sup> (maximum dose: 2 mg) once weekly per protocol; duration of therapy depends on risk status (in combination with dactinomycin, cyclophosphamide, and mesna) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21357783']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21357783'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">VA regimen: Patients &lt;50 years: <b>IV: </b>1.5 mg/m<sup>2</sup> (maximum dose: 2 mg) once weekly per protocol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21357783']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21357783'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a8afedf-539c-4478-9117-60bd80ef6fb6">Small cell lung cancer, recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small cell lung cancer, recurrent (off-label use):</b> CAV regimen: <b>IV: </b>2 mg/dose on day 1 of a 21-day treatment cycle (in combination with cyclophosphamide and doxorubicin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10080612']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10080612'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fad40af8-feee-40d8-ad6f-ea7ae46412ce">Thymoma, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thymoma, advanced (off-label use; based on limited data):</b> ADOC regimen: <b>IV: </b>0.6 mg/m<sup>2</sup> on day 3 every 3 weeks (in combination with cisplatin, doxorubicin, and cyclophosphamide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2049749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2049749'])">Ref</a></span>)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Manufacturer's labeling: </i>Dosing in the prescribing information may not reflect current clinical practice. <b>IV:</b> 1.4 mg/m<sup>2</sup>/dose; frequency may vary based on indication and/or protocol.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Dosage adjustment for concomitant therapy:</i> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991984"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Kenar D. Jhaveri, MD; Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Vincristine pharmacokinetics have not been evaluated in kidney impairment. The following recommendations have been extrapolated from drug characteristics reported in patients with normal kidney function; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment likely to be necessary for any degree of kidney dysfunction (10% to 20% excreted in the urine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7859226','lexi-content-ref-30942181','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7859226','lexi-content-ref-30942181','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (large Vd): No supplemental dose or dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17988304','lexi-content-ref-26689650','lexi-content-ref-15170366','lexi-content-ref-33938097','lexi-content-ref-35948477','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17988304','lexi-content-ref-26689650','lexi-content-ref-15170366','lexi-content-ref-33938097','lexi-content-ref-35948477','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (large Vd): No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989212"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The manufacturer’s labeling recommends the following adjustment: Serum bilirubin &gt;3 mg/dL: Administer 50% of normal dose.</p>
<p style="text-indent:-2em;margin-left:2em;">The following adjustments have also been recommended:</p>
<p style="text-indent:-2em;margin-left:4em;">Floyd 2006: Serum bilirubin 1.5 to 3 mg/dL or transaminases 2 to 3 times ULN or alkaline phosphatase increased: Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Superfin 2007:</p>
<p style="text-indent:-2em;margin-left:6em;">Serum bilirubin 1.5 to 3 mg/dL: Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Serum bilirubin &gt;3 mg/dL: Avoid use.</p></div>
<div class="block adr drugH1Div" id="F234165"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Endocrine &amp; metabolic: SIADH</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension, hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (common)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration, hyperuricemia, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, anorexia, constipation (may involve upper colon fecal impaction), diarrhea, intestinal necrosis, intestinal perforation, nausea, oral mucosa ulcer, paralytic ileus, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Bladder dysfunction (atony), dysuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait, abnormal sensory symptoms (loss of), cranial nerve disorder (including impairment of extraocular movement, laryngeal muscle impairment, paresis, vocal cord paralysis), decreased deep tendon reflex, headache, neuritic pain, paresthesia, sensorimotor neuropathy (dysfunction)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Amyotrophy, foot-drop (including slap gait)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Uric acid nephropathy (acute)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Sore throat</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia, paralysis, parotid pain, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain, jaw pain, limb pain, myalgia, ostealgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharoptosis (Hatzipantelis 2015; Revannasiddaiah 2011), cortical blindness (transient), optic atrophy (with blindness)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory distress syndrome</p></div>
<div class="block coi drugH1Div" id="F234179"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Patients with the demyelinating form of Charcot-Marie-Tooth syndrome.</p></div>
<div class="block war drugH1Div" id="F234162"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vincristine is a vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation. Individuals administering should be experienced in vincristine administration. Extravasation may cause significant irritation. If extravasation occurs, discontinue immediately and initiate appropriate extravasation management, including local injection of hyaluronidase and moderate heat application to the affected area. Use a separate vein to complete administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal effects: Constipation, paralytic ileus, intestinal necrosis and/or perforation may occur; constipation may present as upper colon impaction with an empty rectum (may require flat film of abdomen for diagnosis); generally responds to high enemas and laxatives. All patients should be on a prophylactic bowel management regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurotoxicity: Alterations in mental status such as depression, confusion, or insomnia may occur; neurologic effects are dose-limiting (may require dosage reduction) and may be additive with those of other neurotoxic agents and spinal cord irradiation. Use with caution in patients with pre-existing neuromuscular disease and/or with concomitant neurotoxic agents.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory effects: Acute shortness of breath and severe bronchospasm have been reported with vinca alkaloids, usually when used in combination with mitomycin. Onset may be several minutes to hours after vincristine administration and up to 2 weeks after mitomycin. Progressive dyspnea may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Uric acid nephropathy: Acute uric acid nephropathy has been reported with vincristine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment. Vincristine may be associated with hepatic sinusoidal obstruction syndrome (formerly called veno-occlusive disease), increased risk in children &lt;3 years of age; use with caution in hepatobiliary dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• For IV use only: <b>For IV administration only; fatal if given by other routes.</b> To prevent administration errors, dispense vincristine diluted in a minibag (ISMP 2020). Vincristine should <b>NOT </b>be prepared during the preparation of any medications intended for CNS administration. After preparation, keep vincristine in a location <b>away </b>from the separate storage location recommended for medications intended for CNS administration. Vincristine should <b>NOT </b>be delivered to the patient at the same time with any medications intended for CNS administration (ASCO/ONS [Neuss 2016]).</p></div>
<div class="block foc drugH1Div" id="F234173"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sulfate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vincasar PFS: 1 mg/mL (1 mL [DSC], 2 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (1 mL, 2 mL)</p></div>
<div class="block geq drugH1Div" id="F234158"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16324097"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (vinCRIStine Sulfate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $18.62 - $21.30</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868606"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (1 mL, 2 mL, 5 mL)</p></div>
<div class="block adip drugH1Div" id="F53795311"><span class="drugH1">Additional Information</span>
<p style="text-indent:-2em;margin-left:2em;">Treatment of patients following intrathecal administration of vincristine has included immediate removal of spinal fluid and flushing with Ringer's lactate solution, as well as other solutions, and has not consistently prevented ascending paralysis and/or death.</p>
<p style="text-indent:-2em;margin-left:2em;">In pediatric case reports, aggressive treatments have yielded mixed results. The treatments have included the following (Michelagnoli 1997; Walter 2010):</p>
<p style="text-indent:-2em;margin-left:4em;">Patient remained upright (sitting) and was not allowed to lie down.</p>
<p style="text-indent:-2em;margin-left:4em;">Cerebrospinal fluid was drained and flushed 3 times using a solution of Ringer's lactate with fresh frozen plasma followed by continuous lavage of this solution for at least 24 hours; an adult case report suggests that prolonged lavage may provide greater benefit and reports continuing lavage for 6 days in 1 patient (Qweider 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Additional intrathecal medication was held and additional doses of methotrexate (oral, IV, and intrathecal) were delayed.</p>
<p style="text-indent:-2em;margin-left:4em;">Within 12 hours the following medications were started:</p>
<p style="text-indent:-2em;margin-left:6em;">Glutamic acid 10 g IV over 24 hours followed by 250 to 500 mg orally every 8 hours for 28 days.</p>
<p style="text-indent:-2em;margin-left:6em;">Folinic acid 25 mg IV every 6 hours (one case report included an initial dose of 100 mg IV followed by 25 mg/hour for 24 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">Pyridoxine 50 mg IV every 8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">In one case in an adult patient, progressive paralysis was arrested by the following treatment initiated immediately after the intrathecal injection: As much spinal fluid was removed as could be safely done through lumbar access. The subarachnoid space was flushed with Ringer's lactate solution infused continuously through a catheter in a cerebral lateral ventricle. The fluid was removed through a lumbar access. Fresh frozen plasma was diluted in Ringer's lactate solution and infused through the cerebral ventricular catheter with removal through the lumbar access. Glutamic acid 10 g was given IV over 24 hours followed by 500 mg 3 times daily by mouth for 1 month or until neurological dysfunction stabilized. The role of glutamic acid in this treatment is not certain and may not be essential.</p></div>
<div class="block admp drugH1Div" id="F52614009"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: For IV administration only; fatal if given intrathecally;</b> vincristine should <span style="text-decoration: underline">NOT</span> be delivered to the patient with any medications intended for central nervous system (ie, intrathecal) administration. <b>Note: In order to prevent inadvertent intrathecal administration, the World Health Organization (WHO) and the Institute for Safe Medical Practices (ISMP) recommend dispensing vincristine in a minibag (rather than a syringe)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.1'])">Ref</a></span>). Vincristine should <span style="text-decoration: underline">NOT</span> be prepared during the preparation of any intrathecal medication. After preparation, keep vincristine in a location away from the separate storage location recommended for intrathecal medications.</p>
<p style="text-indent:0em;margin-top:2em;">IV infusion: Administer minibag dose as a short infusion, generally over 5 to 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24418800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24418800'])">Ref</a></span>); administration via gravity instead of infusion pump has also been utilized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30452001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30452001'])">Ref</a></span>). Some protocols utilize a 24-hour continuous IV infusion.</p>
<p style="text-indent:0em;margin-top:2em;">Vincristine is a vesicant and should only be administered IV; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote (see Management of Drug Extravasations for more details); apply dry warm compresses for 20 minutes 4 times a day for 1 to 2 days; elevate extremity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>). Remaining portion of the vincristine dose should be infused through a separate vein.</p></div>
<div class="block adm drugH1Div" id="F234176"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>For IV administration only. Fatal if given by other routes.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dispense vincristine in a minibag or other flexible plastic container (NOT in a syringe)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.1'])">Ref</a></span>). Vincristine should <b>NOT</b> be delivered to the patient at the same time with any medications intended for CNS administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Preferred administration is as a short 5- to 10-minute infusion in a 25 to 50 mL minibag. Some protocols utilize a 24-hour continuous infusion (off-label rate). The minibag may be infused directly into an IV catheter or into a running IV infusion line.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote; remove needle/cannula; apply dry warm compresses for 20 minutes 4 times a day for 1 to 2 days; elevate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>). Remaining portion of the vincristine dose should be infused through a separate vein.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hyaluronidase:</i> If needle/cannula still in place, administer 1 to 6 mL hyaluronidase (150 units/mL) into the existing IV line; the usual dose is 1 mL hyaluronidase for each 1 mL of extravasated drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449','lexi-content-ref-21255716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449','lexi-content-ref-21255716'])">Ref</a></span>). If needle/cannula was removed, inject 1 to 6 mL (150 units/mL) subcutaneously in a clockwise manner using 1 mL for each 1 mL of drug extravasated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21255716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21255716'])">Ref</a></span>) <b>or</b> administer 1 mL (150 units/mL) as 5 separate 0.2 mL injections (using a 25-gauge needle) subcutaneously into the extravasation site (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Polovich.2009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Polovich.2009'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49132727"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F234188"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: Vincristine should be dispensed in a minibag (ISMP 2020). </b>After preparation, keep vincristine in a location <b>away</b> from the separate storage location recommended for medications intended for CNS administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Store intact vials at 2°C to 8°C (36°F to 46°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">IV solution: According to the manufacturer, solutions diluted in NS at concentrations from 0.0015 mg/mL to 0.08 mg/mL and stored at 25°C (77°F) are stable for up to 24 hours when protected from light or 8 hours at normal light conditions. Solutions diluted for infusion in NS or D5W (20 mcg/mL concentration) are reported to be stable for up to 21 days at 4°C (39.2°F) and 25°C (77°F) if protected from light (Beijnen 1989), although the vincristine formulation may have changed since this stability study was conducted. Follow USP 797 recommendations for beyond use dates based on the level of risk for preparation.</p></div>
<div class="block usep drugH1Div" id="F53569478"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, neuroblastoma, non-Hodgkin lymphomas, Wilms tumor, and rhabdomyosarcoma (FDA approved in pediatrics [age not specified] and adults); has also been used in the treatment of central nervous system tumors, chronic lymphocytic leukemia (CLL), Ewing sarcoma, gestational trophoblastic tumors (high-risk), multiple myeloma, retinoblastoma, and small cell lung cancer</p></div>
<div class="block mst drugH1Div" id="F234253"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">VinCRIStine may be confused with vinBLAStine, vinorelbine</p>
<p style="text-indent:-2em;margin-left:4em;">VinCRIStine conventional may be confused with vinCRIStine liposomal</p>
<p style="text-indent:-2em;margin-left:4em;">Oncovin may be confused with Ancobon</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">For IV use only. Fatal if administered by other routes. To prevent fatal inadvertent intrathecal injection, dispense vincristine doses in a flexible plastic container (eg, diluted in 25 to 50 mL of a compatible solution), and <b>NOT</b> a syringe (ISMP 2020). Vincristine should <b>NOT</b> be prepared during the preparation of any medications intended for CNS administration. After preparation, keep vincristine in a location <b>away</b> from the separate storage location recommended for medications intended for CNS administration. Vincristine should <b>NOT</b> be delivered to the patient at the same time with any medications intended for CNS administration.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F234239"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F234167"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of VinCRIStine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of VinCRIStine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of VinCRIStine. Management: Seek alternatives to this combination when possible. If combined, monitor closely for vincristine toxicities (eg, neurotoxicity, gastrointestinal toxicity, myelosuppression).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: VinCRIStine may decrease the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of VinCRIStine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: May increase the serum concentration of VinCRIStine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MitoMYcin (Systemic): Antineoplastic Agents (Vinca Alkaloids) may enhance the adverse/toxic effect of MitoMYcin (Systemic). Specifically, the risk of pulmonary toxicity may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: May increase the serum concentration of VinCRIStine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teniposide: May enhance the neurotoxic effect of VinCRIStine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Drugs Suspected of Causing SIADH may enhance the therapeutic effect of Vasopressin. Specifically, the pressor and antidiuretic effects of vasopressin may be increased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53632823"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who could become pregnant should avoid becoming pregnant during vincristine treatment.</p>
<p style="text-indent:0em;margin-top:2em;">The effect of vincristine alone on male and female fertility is not known; available information is from use in combination with other agents. Recommendations are available for fertility preservation in patients treated with anticancer agents (ASCO [Oktay 2018]).</p></div>
<div class="block pri drugH1Div" id="F10517724"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies, in utero exposure to vincristine may cause fetal harm. However, use in pregnancy has been described (NTP 2013).</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy; the guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided in the first trimester and there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">When multiagent therapy is needed to treat aggressive non-Hodgkin lymphomas during pregnancy, vincristine (as a component of the CHOP [cyclophosphamide, doxorubicin, vincristine, and prednisone] regimen) may be used when indicated (ESMO [Peccatori 2013]; Lishner 2016).</p>
<p style="text-indent:0em;margin-top:2em;">A pregnancy registry is available for all cancers diagnosed during pregnancy at Cooper Health (1-877-635-4499).</p></div>
<div class="block mopp drugH1Div" id="F53569479"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum electrolytes (sodium), hepatic function tests, neurologic examination (prior to each dose), serum uric acid, monitor infusion site, monitor for constipation/ileus and for signs/symptoms of peripheral neuropathy</p></div>
<div class="block pha drugH1Div" id="F234161"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Vincristine binds to tubulin and inhibits microtubule formation, therefore, arresting the cell at metaphase by disrupting the formation of the mitotic spindle; it is specific for the M and S phases. Vincristine may also interfere with nucleic acid and protein synthesis by blocking glutamic acid utilization.</p></div>
<div class="block phk drugH1Div" id="F234178"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> In pediatric patients, significant intrapatient and interpatient variability has been reported (Gidding 1999).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Rapidly removed from bloodstream and tightly bound to tissues; penetrates blood-brain barrier poorly</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic, via CYP3A4</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: 85 hours (range: 19 to 155 hours)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~80%); urine (10% to 20%; &lt;1% as unchanged drug)</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance: In pediatric patients, correlation with diagnosis has been reported; clearance in patients with ALL and non-Hodgkin lymphoma higher than Wilms’ tumor (Gidding 1999):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: Vincristine clearance is lower compared to children; more closely related to body weight than to body surface area (Crom1994)</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 2 to 18 years: Reported means: 357 to 482 mL/minute/m<sup>2</sup>; some suggest faster clearance in children &lt;10 years of age than in adolescents (Crom 1994); however, more recent data does not support this finding nor a dosage reduction in adolescent patients (Frost 2003; Gidding 1999)</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26446832">
<a name="26446832"></a>American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/26446832/pubmed" id="26446832" target="_blank">26446832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27185849">
<a name="27185849"></a>Appel BE, Chen L, Buxton AB, et al. Minimal treatment of low-risk, pediatric lymphocyte-predominant hodgkin lymphoma: a report from the Children's Oncology Group. <i>J Clin Oncol</i>. 2016;34(20):2372-2379.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/27185849/pubmed" id="27185849" target="_blank">27185849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15143082">
<a name="15143082"></a>Arndt C, Hawkins, D, Anderson JR, et al, “Age is a Risk Factor for Chemotherapy-Induced Hepatopathy With Vincristine, Dactinomycin and Cyclophosphamide,” <i>J Clin Oncol</i>, 2004, 22(10):1894-901.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/15143082/pubmed" id="15143082" target="_blank">15143082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.2007">
<a name="Aronoff.2007"></a>Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 102, 174.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22665535">
<a name="22665535"></a>Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. <i>J Clin Oncol</i>. 2012;30(21):2641-2647.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/22665535/pubmed" id="22665535" target="_blank">22665535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11877270">
<a name="11877270"></a>Avramis VI, Sencer S, Periclou AP, et al, “A Randomized Comparison of Native <i>Escherichia coli</i> Asparaginase and Polyethylene Glycol Conjugated Asparaginase for Treatment of Children With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia: A Children's Cancer Group Study,” <i>Blood</i>, 2002, 99(6):1986-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/11877270/pubmed" id="11877270" target="_blank">11877270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30452001">
<a name="30452001"></a>Beaver C. Vincristine minibag administration: a quality improvement project to minimize medical errors. <i>Clin J Oncol Nurs</i>. 2018;22(6):669-672.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/30452001/pubmed" id="30452001" target="_blank">30452001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2709240">
<a name="2709240"></a>Beijnen JH, Vendrig DE, Underberg WJ. Stability of vinca alkaloid anticancer drugs in three commonly used infusion fluids. <i>J Parenter Sci Technol</i>. 1989;43(2):84-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/2709240/pubmed" id="2709240" target="_blank">2709240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12531809">
<a name="12531809"></a>Bostrom BC, Sensel MR, Sather HN, et al, “Dexamethasone Versus Prednisone and Daily Oral Versus Weekly Intravenous Mercaptopurine for Patients With Standard-Risk Acute Lymphoblastic Leukemia: A Report from the Children's Cancer Group,” <i>Blood</i>, 2003, 101(10):3809-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12531809/pubmed" id="12531809" target="_blank">12531809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8648381">
<a name="8648381"></a>Bowman WP, Shuster JJ, Cook B, et al, “Improved Survival for Children With B-Cell Acute Lymphoblastic Leukemia and Stage IV Small Noncleaved-Cell Lymphoma: A Pediatric Oncology Group Study,” <i>J Clin Oncol</i>, 1996, 14(4):1252-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/8648381/pubmed" id="8648381" target="_blank">8648381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20855843">
<a name="20855843"></a>Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.<i> J Clin Oncol.</i> 2010;28(30):4601-4608. doi: 10.1200/JCO.2009.27.1932.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/20855843/pubmed" id="20855843" target="_blank">20855843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27050206">
<a name="27050206"></a>Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. <i>N Engl J Med</i> 2016;374(14):1344-1355. doi: 10.1056/NEJMoa1500925.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/27050206/pubmed" id="27050206" target="_blank">27050206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16782910">
<a name="16782910"></a>Cairncross G, Berkey B, Shaw E, et al, “Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402,” <i>J Clin Oncol</i>, 2006, 24(18):2707-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/16782910/pubmed" id="16782910" target="_blank">16782910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23071247">
<a name="23071247"></a>Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. <i>J Clin Oncol</i>. 2013;31(3):337-343.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/23071247/pubmed" id="23071247" target="_blank">23071247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17138821">
<a name="17138821"></a>Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. <i>Blood</i>. 2007;109(7):2736-2743.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/17138821/pubmed" id="17138821" target="_blank">17138821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36322844">
<a name="36322844"></a>Castellino SM, Pei Q, Parsons SK, et al. Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin's lymphoma. <i>N Engl J Med</i>. 2022;387(18):1649-1660. doi:10.1056/NEJMoa2206660<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/36322844/pubmed" id="36322844" target="_blank">36322844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15611503">
<a name="15611503"></a>Chi SN, Gardner SL, Levy AS, et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. <i>J Clin Oncol</i>. 2004;22(24):4881-4887.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/15611503/pubmed" id="15611503" target="_blank">15611503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31437753">
<a name="31437753"></a>Codacci-Pisanelli G, Honeywell RJ, Asselin N, et al. Breastfeeding during R-CHOP chemotherapy: please abstain! <i>Eur J Cancer</i>. 2019;119:107-111. doi:10.1016/j.ejca.2019.07.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/31437753/pubmed" id="31437753" target="_blank">31437753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11807147">
<a name="11807147"></a>Coiffier B, Lepage E, Briere J, et al, “CHOP Chemotherapy Plus Rituximab Compared With CHOP Alone in Elderly Patients With Diffuse Large-B-Cell Lymphoma,” <i>N Engl J Med</i>, 2002, 346(4):235-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/11807147/pubmed" id="11807147" target="_blank">11807147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11408506">
<a name="11408506"></a>Crist WM, Anderson JR, Meza JL, et al, "Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic Disease," <i>J Clin Oncol</i>, 2001, 19(12):3091-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/11408506/pubmed" id="11408506" target="_blank">11408506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7931891">
<a name="7931891"></a>Crom WR, deGraaf SS, Synold T, et al, “Pharmacokinetics of Vincristine in Children and Adolescents With Acute Lymphocytic Leukemia,” <i>J Pediatr</i>, 1994, 125(4):642-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/7931891/pubmed" id="7931891" target="_blank">7931891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12488408">
<a name="12488408"></a>DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. <i>J Clin Oncol</i>. 2002;20(24):4643-4648.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12488408/pubmed" id="12488408" target="_blank">12488408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25079173">
<a name="25079173"></a>DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. <i>Leukemia.</i> 2015;29(3):526-534. doi: 10.1038/leu.2014.229.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/25079173/pubmed" id="25079173" target="_blank">25079173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12802024">
<a name="12802024"></a>Diehl V, Franklin J, Pfreundschuh M, et al, “Standard and Increased-Dose BEACOPP Chemotherapy Compared With COPP-ABVD for Advanced Hodgkin's Disease,” <i>N Engl J Med</i>, 2003, 348(24):2386-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12802024/pubmed" id="12802024" target="_blank">12802024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23574119">
<a name="23574119"></a>Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. <i>N Engl J Med</i>. 2013;368(15):1408-1416.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/23574119/pubmed" id="23574119" target="_blank">23574119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14675675">
<a name="14675675"></a>Escobar PF, Lurain JR, Singh DK, et al, “Treatment of High-Risk Gestational Trophoblastic Neoplasia With Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide, and Vincristine Chemotherapy,” <i>Gynecol Oncol</i>, 2003, 91(3):552-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/14675675/pubmed" id="14675675" target="_blank">14675675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33384141">
<a name="33384141"></a>Eiriksson L, Dean E, Sebastianelli A, et al. Guideline no. 408: management of gestational trophoblastic diseases. <i>J Obstet Gynaecol Can</i>. 2021;43(1):91-105.e1. doi:10.1016/j.jogc.2020.03.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/33384141/pubmed" id="33384141" target="_blank">33384141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6284345">
<a name="6284345"></a>Evans AE, Land VJ, Newton WA, Randolph JG, Sather HN, Tefft M. Combination chemotherapy (vincristine, adriamycin, cyclophosphamide, and 5-fluorouracil) in the treatment of children with malignant hepatoma. <i>Cancer</i>. 1982;50(5):821-826.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/6284345/pubmed" id="6284345" target="_blank">6284345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17988304">
<a name="17988304"></a>Feldmann G, Nattermann J, Gerhardt T, et al. Partial remission of a newly diagnosed diffuse large B-cell Non-Hodgkin's lymphoma in a hemodialysis patient after administration of immuno-chemotherapy with rituximab-CHOP.<i> Int J Lab Hematol</i>. 2007 Dec;29(6):469-473. doi:10.1111/j.1365-2257.2006.00879.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/17988304/pubmed" id="17988304" target="_blank">17988304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9307187">
<a name="9307187"></a>Fenig E, Brenner B, Katz A, Rakovsky E, Hana MB, Sulkes A. The role of radiation therapy and chemotherapy in the treatment of Merkel cell carcinoma. <i>Cancer</i>. 1997;80(5):881-885.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/9307187/pubmed" id="9307187" target="_blank">9307187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16473644">
<a name="16473644"></a>Floyd J, Mirza I, Sachs B, et al, "Hepatotoxicity of Chemotherapy," <i>Semin Oncol</i>, 2006, 33(1):50-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/16473644/pubmed" id="16473644" target="_blank">16473644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16234530">
<a name="16234530"></a>Floyd JD, Nguyen DT, Lobins RL, et al, "Cardiotoxicity of Cancer Therapy," <i>J Clin Oncol</i>. 2005, 23(30):7685-96.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/16234530/pubmed" id="16234530" target="_blank">16234530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24712411">
<a name="24712411"></a>Follows GA, Ardeshna KM, Barrington SF, et al. Guidelines for the first line management of classical Hodgkin lymphoma. <i>Br J Haematol</i>. 2014;166(1):34-49. doi:10.1111/bjh.12878<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/24712411/pubmed" id="24712411" target="_blank">24712411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2049749">
<a name="2049749"></a>Fornasiero A, Daniele O, Ghiotto C, et al, “Chemotherapy for Invasive thymoma. A 13-year Experience,” <i>Cancer</i>, 1991, 68(1):30-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/2049749/pubmed" id="2049749" target="_blank">2049749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25311218">
<a name="25311218"></a>Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. <i>J Clin Oncol</i>. 2014;32(32):3651-3658.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/25311218/pubmed" id="25311218" target="_blank">25311218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10623688">
<a name="10623688"></a>Friedman DL, Himelstein B, Shields CL, et al, "Chemoreduction and Local Ophthalmic Therapy for Intraocular Retinoblastoma," <i>J Clin Oncol</i>, 2000, 18(1):12-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/10623688/pubmed" id="10623688" target="_blank">10623688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12839283">
<a name="12839283"></a>Frost BM, Lönnerholm G, Koopmans P, et al, "Vincristine in Childhood Leukaemia: No Pharmacokinetic Rationale for Dose Reduction in Adolescents," Acta Paediatr, 2003, 92(5):551-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12839283/pubmed" id="12839283" target="_blank">12839283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17233819">
<a name="17233819"></a>García-Suárez J, Bañas H, Arribas I, De Miguel D, Pascual T, Burgaleta C. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. <i>Br J Haematol</i>. 2007;136(2):276-285.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/17233819/pubmed" id="17233819" target="_blank">17233819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10453721">
<a name="10453721"></a>Gidding CE, Meeuwsen-de Boer GJ, Koopmans P, Uges DR, Kamps WA, de Graaf SS. Vincristine pharmacokinetics after repetitive dosing in children. <i>Cancer Chemother Pharmacol</i>. 1999;44(3):203-209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/10453721/pubmed" id="10453721" target="_blank">10453721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24418800">
<a name="24418800"></a>Gilbar P, Chambers CR, Larizza M. Medication safety and the administration of intravenous vincristine: international survey of oncology pharmacists. <i>J Oncol Pharm Pract</i>. 2015;21(1):10-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/24418800/pubmed" id="24418800" target="_blank">24418800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29082519">
<a name="29082519"></a>Giulino-Roth L, O'Donohue T, Chen Z, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. <i>Br J Haematol</i>. 2017;179(5):739-747.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/29082519/pubmed" id="29082519" target="_blank">29082519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22940833">
<a name="22940833"></a>Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. <i>Leukemia</i>. 2013;27(5):1174-1177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/22940833/pubmed" id="22940833" target="_blank">22940833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25066629">
<a name="25066629"></a>Goldman S, Smith L, Galardy P, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. <i>Br J Haematol</i>. 2014;167(3):394-401.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/25066629/pubmed" id="25066629" target="_blank">25066629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19349548">
<a name="19349548"></a>Granowetter L, Womer R, Devidas M, et al, "Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study," <i>J Clin Oncol</i>, 2009, 27(15):2536-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/19349548/pubmed" id="19349548" target="_blank">19349548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9850017">
<a name="9850017"></a>Green DM, Breslow NE, Beckwith JB, et al, “Effect of Duration of Treatment on Treatment Outcome and Cost of Treatment for Wilms' Tumor: A Report From the National Wilms' Tumor Study Group,” <i>J Clin Oncol</i>, 1998, 16(12):3744-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/9850017/pubmed" id="9850017" target="_blank">9850017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16547940">
<a name="16547940"></a>Green DM, Cotton CA, Malogolowkin M, et al, “Treatment of Wilms Tumor Relapsing After Initial Treatment With Vincristine and Actinomycin D: A Report From the National Wilms Tumor Study Group,” <i>Pediatr Blood Cancer</i>, 2007, 48(5):493-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/16547940/pubmed" id="16547940" target="_blank">16547940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12594313">
<a name="12594313"></a>Grier HE, Krailo MD, Tarbell NJ, et al, “Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone,” <i>N Engl J Med</i>, 2003, 348(8):694-701.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12594313/pubmed" id="12594313" target="_blank">12594313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26862280">
<a name="26862280"></a>Hatzipantelis E, Kyriakidis I, Pavlou E, Pavlidou E. Bilateral Eyelid Ptosis, Attributed to Vincristine, Treated Successfully with Pyridoxine and Thiamine in a Child with Acute Lymphoblastic Leukemia. <i>Toxicol Int</i>. 2015;22(1):162-164. doi:10.4103/0971-6580.172275<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/26862280/pubmed" id="26862280" target="_blank">26862280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16123223">
<a name="16123223"></a>Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. <i>Blood</i>. 2005;106(12):3725-3732. doi: 10.1182/blood-2005-01-0016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/16123223/pubmed" id="16123223" target="_blank">16123223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2538577">
<a name="2538577"></a>Hong WK, Nicaise C, Larson R, et al, “Etoposide Combined With Cyclophosphamide Plus Vincristine Compared With Doxorubicin Plus Cyclophosphamide Plus Vincristine and With High-Dose Cyclophosphamide Plus Vincristine in the Treatment of Small-Cell Carcinoma of the Lung: A Randomized Trial of the Bristol Lung Cancer Study Group,” <i>J Clin Oncol</i>, 1989, 7(4):450-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/2538577/pubmed" id="2538577" target="_blank">2538577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11821442">
<a name="11821442"></a>Horning SJ, Hoppe RT, Breslin S, et al, “Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical Trial,” <i>J Clin Oncol</i>, 2002, 20(3):630-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/11821442/pubmed" id="11821442" target="_blank">11821442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10694546">
<a name="10694546"></a>Horning SJ, Williams J, Bartlett NL, et al, “Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492,” <i>J Clin Oncol</i>, 2000, 18(5):972-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/10694546/pubmed" id="10694546" target="_blank">10694546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18780317">
<a name="18780317"></a>Huang H, Abraham J, Hung E, et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. <i>Cancer</i>. 2008;113(8):2020-2028.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/18780317/pubmed" id="18780317" target="_blank">18780317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29863974">
<a name="29863974"></a>Huguet F, Chevret S, Lequay T, et al; Group of Research on Adult ALL (GRAALL). Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial.<i> J Clin Oncol.</i> 2018;36(24):2514-2523. doi: 10.1200/JCO.2017.76.8192.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/29863974/pubmed" id="29863974" target="_blank">29863974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19124805">
<a name="19124805"></a>Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. <i>J Clin Oncol</i>. 2009;27(6):911-918.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/19124805/pubmed" id="19124805" target="_blank">19124805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medicine Practices (ISMP). <i>ISMP Targeted Medication Safety Best Practices for Hospitals</i>. https://www.ismp.org/sites/default/files/attachments/2020-02/2020-2021%20TMSBP-%20FINAL_1.pdf. Published February 21, 2020. Accessed January 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15481055">
<a name="15481055"></a>Kantarjian H, Thomas D, O'Brien S, et al, “Long-Term Follow-Up Results of Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (Hyper-CVAD), A Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia,” <i>Cancer</i>, 2004, 101(12):2788-801.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/15481055/pubmed" id="15481055" target="_blank">15481055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12078889">
<a name="12078889"></a>Kelly KM, Hutchinson RJ, Sposto R, et al, "Feasibility of Upfront Dose-Intensive Chemotherapy in Children With Advanced-Stage Hodgkin's Lymphoma: Preliminary Results From the Children's Cancer Group Study CCG-59704," <i>Ann Oncol</i>, 2002, 13(Suppl 1):107-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12078889/pubmed" id="12078889" target="_blank">12078889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26065651">
<a name="26065651"></a>Kim DY, Joo YD, Lim SN, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. <i>Blood</i>. 2015;126(6):746-756.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/26065651/pubmed" id="26065651" target="_blank">26065651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7859226">
<a name="7859226"></a>Kintzel PE and Dorr RT, “Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,” <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/7859226/pubmed" id="7859226" target="_blank">7859226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12972518">
<a name="12972518"></a>Kolb EA, Kushner BH, Gorlick R, et al, “Long-Term Event-Free Survival After Intensive Chemotherapy for Ewing's Family of Tumors in Children and Young Adults,” <i>J Clin Oncol</i>, 2003, 21(18):3423-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12972518/pubmed" id="12972518" target="_blank">12972518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20564411">
<a name="20564411"></a>Kushner BH, Kramer K, Modak S, Qin LX, Cheung NK. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. <i>Cancer</i>. 2010;116(12):3054-3060.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/20564411/pubmed" id="20564411" target="_blank">20564411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7527454">
<a name="7527454"></a>Kushner BH, LaQuaglia MP, Bonilla MA, et al, “Highly Effective Induction Therapy for Stage 4 Neuroblastoma in Children Over 1 Year of Age,” <i>J Clin Oncol</i>, 1994, 12(12):2607-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/7527454/pubmed" id="7527454" target="_blank">7527454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27114587">
<a name="27114587"></a>Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children's Oncology Group Study AALL0232. <i>J Clin Oncol</i>. 2016;34(20):2380-2388.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/27114587/pubmed" id="27114587" target="_blank">27114587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7718875">
<a name="7718875"></a>Larson RA, Dodge RK, Burns CP, et al, “A Five-Drug Remission Induction Regimen With Intensive Consolidation for Adults With Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8811,” <i>Blood</i>, 1995, 85(8):2025-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/7718875/pubmed" id="7718875" target="_blank">7718875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3540519">
<a name="3540519"></a>Legha SS, "Vincristine Neurotoxicity. Pathophysiology and Management," <i>Med Toxicol</i>, 1986, 1(6):421-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/3540519/pubmed" id="3540519" target="_blank">3540519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11051233">
<a name="11051233"></a>Levin VA, Uhm JH, Jaeckle KA, et al. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N’-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. <i>Clin Cancer Res.</i> 2000;6(10):3878-3884.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/11051233/pubmed" id="11051233" target="_blank">11051233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26628463">
<a name="26628463"></a>Lishner M, Avivi I, Apperley JF, et al. Hematologic malignancies in pregnancy: management guidelines from an international consensus meeting. <i>J Clin Oncol</i>. 2016;34(5):501-508. doi:10.1200/JCO.2015.62.4445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/26628463/pubmed" id="26628463" target="_blank">26628463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17086804">
<a name="17086804"></a>Lurain JR, Singh DK, Schink JC. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. <i>J Reprod Med</i>. 2006;51(10):767-772<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/17086804/pubmed" id="17086804" target="_blank">17086804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8622041">
<a name="8622041"></a>Magrath I, Adde M, Shad A, et al, “Adults and Children With Small Non-Cleaved-Cell Lymphoma Have a Similar Excellent Outcome When Treated With the Same Chemotherapy Regimen,” <i>J Clin Oncol</i>, 1996, 14(3):925-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/8622041/pubmed" id="8622041" target="_blank">8622041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28976863">
<a name="28976863"></a>Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. <i>N Engl J Med</i>. 2017;377(14):1331-1344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/28976863/pubmed" id="28976863" target="_blank">28976863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494430">
<a name="15494430"></a>Marcus R, Imrie K, Belch A, et al, “CVP Chemotherapy Plus Rituximab Compared With CVP as First-Line Treatment for Advanced Follicular Lymphoma,” <i>Blood</i>, 2005, 105(4):1417-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/15494430/pubmed" id="15494430" target="_blank">15494430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9262750">
<a name="9262750"></a>McCune JS and Lindley C, "Appropriateness of Maximum-Dose Guidelines for Vincristine," <i>Am J Health Syst Pharm</i>, 1997, 54(15):1755-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/9262750/pubmed" id="9262750" target="_blank">9262750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18612102">
<a name="18612102"></a>Mead GM, Barrans SL, Qian W, et al, "A Prospective Clinicopathologic Study of Dose-Modified CODOX-M/IVAC in Patients With Sporadic Burkitt Lymphoma Defined Using Cytogenetic and Immunophenotypic Criteria (MRC/NCRI LY10 Trial)," <i>Blood</i>, 2008, 112(6):2248-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/18612102/pubmed" id="18612102" target="_blank">18612102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12181251">
<a name="12181251"></a>Mead GM, Sydes MR, Walewski J, et al, "An International Evaluation of CODOX-M and CODOX-M Alternating With IVAC in Adult Burkitt's Lymphoma: Results of United Kingdom Lymphoma Group LY06 Study," <i>Ann Oncol</i>, 2002, 13(8):1264-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12181251/pubmed" id="12181251" target="_blank">12181251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9375755">
<a name="9375755"></a>Michelagnoli MP, Bailey CC, Wilson I, Livingston J, Kinsey SE. Potential salvage therapy for inadvertent intrathecal administration of vincristine. <i>Br J Haematol</i>. 1997;99(2):364-367.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/9375755/pubmed" id="9375755" target="_blank">9375755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moccia.2009">
<a name="Moccia.2009"></a>Moccia AA, Schaff K, Hoskins P, et al. R-CHOP with etoposide substituted for doxorubicin (R-CEOP): excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines. <i>Blood.</i> 2009;114(22), abstract 408.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24101038">
<a name="24101038"></a>Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. <i>J Clin Oncol</i>. 2013;31(31):3971-3979.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/24101038/pubmed" id="24101038" target="_blank">24101038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19588521">
<a name="19588521"></a>Moore A and Pinkerton R, "Vincristine: Can Its Therapeutic Index Be Enhanced?" <i>Pediatr Blood Cancer</i>, 2009, 53(7):1180-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/19588521/pubmed" id="19588521" target="_blank">19588521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21276754">
<a name="21276754"></a>Morgan C, Tillett T, Braybrooke J, et al, "Management of Uncommon Chemotherapy-Induced Emergencies," <i>Lancet Oncol</i>, 2011, 12(8):806-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/21276754/pubmed" id="21276754" target="_blank">21276754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NTP.1">
<a name="NTP.1"></a>National Toxicology Program (NTP) - US Department of Health and Human Services. Cancer chemotherapy use during pregnancy. <a href="http://ntp.niehs.nih.gov/pubhealth/hat/noms/chemo/index.html" target="_blank">http://ntp.niehs.nih.gov/pubhealth/hat/noms/chemo/index.html</a>. Published May 1, 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27868581">
<a name="27868581"></a>Neuss MN, Gilmore TR, Belderson KM, et al. 2016 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards, including standards for pediatric oncology. <i>J Oncol Pract</i>. 2016;12(12):1262-1271. doi:10.1200/JOP.2016.017905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/27868581/pubmed" id="27868581" target="_blank">27868581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26689650">
<a name="26689650"></a>Ochi Y, Hiramoto N, Ono Y, et al. Tolerability and efficacy of rituximab-containing immunochemotherapy in patients with B-cell non-Hodgkin lymphoma receiving hemodialysis. <i>Leuk Lymphoma</i>. 2016;57(8):1945-1948. doi:10.3109/10428194.2015.1115033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/26689650/pubmed" id="26689650" target="_blank">26689650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29620997">
<a name="29620997"></a>Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. <i>J Clin Oncol</i>. 2018;36(19):1994-2001. doi:10.1200/JCO.2018.78.1914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/29620997/pubmed" id="29620997" target="_blank">29620997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25568347">
<a name="25568347"></a>Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. <i>Blood</i>. 2015;125(9):1403-1410.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/25568347/pubmed" id="25568347" target="_blank">25568347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10894865">
<a name="10894865"></a>Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. <i>J Clin Oncol</i>. 2000;18(14):2665-2675.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/10894865/pubmed" id="10894865" target="_blank">10894865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16943538">
<a name="16943538"></a>Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. <i>J Clin Oncol</i>. 2006;24(25):4202-4208. doi: 10.1200/JCO.2006.06.4980.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/16943538/pubmed" id="16943538" target="_blank">16943538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-vi170. doi:10.1093/annonc/mdt199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Perez Fidalgo JA, García Fabregat L, Cervantes A, et al, “Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,” <i>Ann Oncol</i>, 2012, 23(Suppl 7):167-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14982884">
<a name="14982884"></a>Pfreundschuh M, Trümper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. <i>Blood</i>. 2004;104(3):626-633. doi: 10.1182/blood-2003-06-2094.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/14982884/pubmed" id="14982884" target="_blank">14982884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17658395">
<a name="17658395"></a>Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. <i>Lancet</i>. 2007;370(9583):240-250.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/17658395/pubmed" id="17658395" target="_blank">17658395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Polovich.2009">
<a name="Polovich.2009"></a>Polovich M, Whitford JN and Olsen M, <i>Chemotherapy and Biotherapy Guidelines and Recommendations for Practice</i>, 3rd ed, Pittsburgh, PA: Oncology Nursing Society, 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7799012">
<a name="7799012"></a>Pritchard J, Imeson J, Barnes J, et al, "Results of the United Kingdom Children's Cancer Study Group First Wilms' Tumor Study," <i>J Clin Oncol</i>, 1995, 13(1):124-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/7799012/pubmed" id="7799012" target="_blank">7799012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17355029">
<a name="17355029"></a>Qweider M, Gilsbach JM, Rohde V. Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report. <i>J Neurosurg Spine</i>. 2007;6(3):280-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/17355029/pubmed" id="17355029" target="_blank">17355029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21357783">
<a name="21357783"></a>Raney RB, Walterhouse DO, Meza JL, et al. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. <i>J Clin Oncol</i>. 2011;29(10):1312-1318.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/21357783/pubmed" id="21357783" target="_blank">21357783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20466853">
<a name="20466853"></a>Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. <i>Blood</i>. 2010;116(12):2070-2077.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/20466853/pubmed" id="20466853" target="_blank">20466853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22696700">
<a name="22696700"></a>Revannasiddaiah S, Bhattacharyya T. Vincristine-induced unilateral ptosis with serendipitous response to modafinil. <i>BMJ Case Rep</i>. 2011;2011:bcr0720103178. Published 2011 May 3. doi:10.1136/bcr.07.2010.3178<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/22696700/pubmed" id="22696700" target="_blank">22696700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10552938">
<a name="10552938"></a>Reiter A, Schrappe M, Tiemann M, et al, “Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored Intensification of Therapy: A Report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90,” <i>Blood</i>, 1999, 94(10):3294-306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/10552938/pubmed" id="10552938" target="_blank">10552938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16404741">
<a name="16404741"></a>Rifkin RM, Gregory SA, Mohrbacher A, et al, “Pegylated Liposomal Doxorubicin, Vincristine, and Dexamethasone Provide Significant Reduction in Toxicity Compared With Doxorubicin, Vincristine, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma: A Phase III Multicenter Randomized Trial,” <i>Cancer</i>, 2006, 106(4):848-58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/16404741/pubmed" id="16404741" target="_blank">16404741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24428673">
<a name="24428673"></a>Rizzieri DA, Johnson JL, Byrd JC, et al; Alliance for Clinical Trials In Oncology (ACTION). Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and leukemia group B study 10 002. <i>Br J Haematol</i>. 2014;165(1);102-111. doi: 10.1111/bjh.12736.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/24428673/pubmed" id="24428673" target="_blank">24428673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12743157">
<a name="12743157"></a>Rodriguez-Galindo C, Wilson MW, Haik BG, et al, "Treatment of Intraocular Retinoblastoma With Vincristine and Carboplatin," <i>J Clin Oncol</i>, 2003, 21(10):2019-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12743157/pubmed" id="12743157" target="_blank">12743157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27121472">
<a name="27121472"></a>Rousselot P, Coudé MM, Gokbuget N, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. <i>Blood</i>. 2016;128(6):774-782.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/27121472/pubmed" id="27121472" target="_blank">27121472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16105981">
<a name="16105981"></a>Rowe JM, Buck G, Burnett AK, et al; ECOG; MRC/NCRI Adult Leukemia Working Party. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. <i>Blood</i>. 2005;106(12): 3760-3767. doi: 10.1182/blood-2005-04-1623.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/16105981/pubmed" id="16105981" target="_blank">16105981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14583756">
<a name="14583756"></a>Rubie H, Coze C, Plantaz D, et al. Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy. <i>Br J Cancer</i>. 2003;89(9):1605-1609.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/14583756/pubmed" id="14583756" target="_blank">14583756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21172879">
<a name="21172879"></a>Rubie H, De Bernardi B, Gerrard M, et al. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. <i>J Clin Oncol</i>. 2011;29(4):449-455.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/21172879/pubmed" id="21172879" target="_blank">21172879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9649151">
<a name="9649151"></a>Rubie H, Michon J, Plantaz D, et al, “Unresectable Localized Neuroblastoma: Improved Survival After Primary Chemotherapy Including Carboplatin-Etoposide. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique (SFOP),” <i>Br J Cancer</i>, 1998, 77(12):2310-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/9649151/pubmed" id="9649151" target="_blank">9649151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11464897">
<a name="11464897"></a>Rubie H, Plantaz D, Coze C, et al, "Localised and Unresectable Neuroblastoma in Infants: Excellent Outcome With Primary Chemotherapy. Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique," <i>Med Pediatr Oncol</i>, 2001, 36(1):247-50.S<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/11464897/pubmed" id="11464897" target="_blank">11464897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20660290">
<a name="20660290"></a>Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. <i>Blood</i>. 2010;116(18):3418-3425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/20660290/pubmed" id="20660290" target="_blank">20660290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21255716">
<a name="21255716"></a>Schulmeister L, "Extravasation Management: Clinical Update," <i>Semin Oncol Nurs</i>, 2011, 27(1):82-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/21255716/pubmed" id="21255716" target="_blank">21255716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19584400">
<a name="19584400"></a>Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. <i>Blood</i>. 2009;114(10):2051-2059.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/19584400/pubmed" id="19584400" target="_blank">19584400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23334272">
<a name="23334272"></a>Seif AE, Naranjo A, Baker DL, et al. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. <i>Bone Marrow Transplant</i>. 2013;48(7):947-952.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/23334272/pubmed" id="23334272" target="_blank">23334272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17947720">
<a name="17947720"></a>Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. <i>J Clin Oncol</i>. 2007;25(30):4730-4735. doi: 10.1200/JCO.2007.12.5062.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/17947720/pubmed" id="17947720" target="_blank">17947720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851558">
<a name="22851558"></a>Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. <i>J Clin Oncol.</i> 2012;30(25):3065-3070. doi: 10.1200/JCO.2011.35.8598.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/22851558/pubmed" id="22851558" target="_blank">22851558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12470138">
<a name="12470138"></a>Shields CL, Honavar SG, Meadows AT, et al, "Chemoreduction for Unilateral Retinoblastoma," <i>Arch Ophthalmol</i>, 2002, 120(12):1653-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12470138/pubmed" id="12470138" target="_blank">12470138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2988740">
<a name="2988740"></a>Slayton RE, Park RC, Silverberg SG, et al, “Vincristine, Dactinomycin, and Cyclophosphamide in the Treatment of Malignant Germ Cell Tumors of the Ovary. A Gynecologic Oncology Group Study (A Final Report),” <i>Cancer</i>, 1985, 56(2):243-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/2988740/pubmed" id="2988740" target="_blank">2988740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12743160">
<a name="12743160"></a>Stefanou A and Dooley M, “Simple Method to Eliminate the Risk of Inadvertent Intrathecal Vincristine Administration,” <i>J Clin Oncol</i>, 2006, 21(10):2044.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12743160/pubmed" id="12743160" target="_blank">12743160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30658992">
<a name="30658992"></a>Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. <i>Blood</i>. 2019;133(14):1548-1559. doi: 10.1182/blood-2018-10-881961.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/30658992/pubmed" id="30658992" target="_blank">30658992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17914077">
<a name="17914077"></a>Superfin D, Iannucci AA, and Davies AM, “Commentary: Oncologic Drugs in Patients With Organ Dysfunction: A Summary,” <i>Oncologist</i>, 2007, 12(9):1070-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/17914077/pubmed" id="17914077" target="_blank">17914077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12860801">
<a name="12860801"></a>Sussman DA, Escalona-Benz E, Benz MS, et al, "Comparison of Retinoblastoma Reduction for Chemotherapy vs External Beam Radiotherapy," <i>Arch Ophthalmol</i>, 2003, 121(7):979-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12860801/pubmed" id="12860801" target="_blank">12860801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10856110">
<a name="10856110"></a>Tai PT, Yu E, Winquist E, et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. <i>J Clin Oncol</i>. 2000;18(12):2493-2499. doi: 10.1200/JCO.2000.18.12.2493.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/10856110/pubmed" id="10856110" target="_blank">10856110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14551133">
<a name="14551133"></a>Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. <i>Blood</i>. 2004;103(12):4396-4407.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/14551133/pubmed" id="14551133" target="_blank">14551133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16502413">
<a name="16502413"></a>Thomas DA, Faderi S, O’Brien S, et al, “Chemoimmunotherapy With Hyper-CVAD Plus Rituximab for the Treatment of Adult Burkitt and Burkitt-Type Lymphoma or Acute Lymphoblastic Leukemia,” <i>Cancer</i>, 2006, 106(7):1569-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/16502413/pubmed" id="16502413" target="_blank">16502413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15170366">
<a name="15170366"></a>Tomita M, Aoki Y, Tanaka K. Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs. <i>Clin Pharmacokinet</i>. 2004;43(8):515-527. doi:10.2165/00003088-200443080-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/15170366/pubmed" id="15170366" target="_blank">15170366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12655528">
<a name="12655528"></a>Tsimberidou AM, Kantarjian HM, Cortes J, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. <i>Cancer.</i> 2003;97(7):1711-1720. doi: 10.1002/cncr.11238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12655528/pubmed" id="12655528" target="_blank">12655528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16710033">
<a name="16710033"></a>Tsimberidou AM, O’Brien S, Khouri I, et al. Clinical outcomes and prognostic factors in patients with Richter’s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. <i>J Clin Oncol.</i> 2006;24(15):2343-2351. doi: 10.1200/JCO.2005.05.0187.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/16710033/pubmed" id="16710033" target="_blank">16710033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23071237">
<a name="23071237"></a>van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. <i>J Clin Oncol</i>. 2013;31(3):344-350.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/23071237/pubmed" id="23071237" target="_blank">23071237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16782911">
<a name="16782911"></a>van den Bent MJ, Carpentier AF, Brandes AA, et al, “Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival But Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial,” <i>J Clin Oncol</i>, 2006, 24(18):2715-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/16782911/pubmed" id="16782911" target="_blank">16782911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vincasar.1">
<a name="Vincasar.1"></a>Vincasar PFS (vincristine sulfate) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.1">
<a name="Hospira.1"></a>Vincristine sulfate [prescribing information]. Lake Forest, IL: Hospira Inc; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10080612">
<a name="10080612"></a>von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. <i>J Clin Oncol</i>. 1999;17(2):658-667.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/10080612/pubmed" id="10080612" target="_blank">10080612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20445422">
<a name="20445422"></a>Walter AW. Regarding "Intrathecal vincristine: 3 fatal cases and a review of the literature." <i>J Pediatr Hematol Oncol</i>. 2010;32(4):336-337.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/20445422/pubmed" id="20445422" target="_blank">20445422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21298768">
<a name="21298768"></a>Walterhouse DO, Meza JL, Breneman JC, et al. Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group. <i>Pediatr Blood Cancer</i>. 2011;57(1):76-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/21298768/pubmed" id="21298768" target="_blank">21298768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25267746">
<a name="25267746"></a>Walterhouse DO, Pappo AS, Meza JL, et al. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. <i>J Clin Oncol</i>. 2014;32(31):3547-3552.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/25267746/pubmed" id="25267746" target="_blank">25267746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11929754">
<a name="11929754"></a>Wilson WH, Grossbard ML, Pittaluga S, et al, “Dose-Adjusted EPOCH Chemotherapy for Untreated Large B-Cell Lymphomas: A Pharmacodynamic Approach With High Efficacy,” <i>Blood</i>, 2002, 99(8):2685-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/11929754/pubmed" id="11929754" target="_blank">11929754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6937637">
<a name="6937637"></a>Woods WG, O'Leary M, and Nesbit ME, “Life-Threatening Neuropathy and Hepatotoxicity in Infants During Induction Therapy for Acute Lymphoblastic Leukemia,” <i>J Pediatr</i>, 1981, 98(4):642-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/6937637/pubmed" id="6937637" target="_blank">6937637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23863060">
<a name="23863060"></a>Woessmann W, Lisfeld J, Burkhardt B; NHL-BFM Study Group. Therapy in primary mediastinal B-cell lymphoma. <i>N Engl J Med</i>. 2013;369(3):282.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/23863060/pubmed" id="23863060" target="_blank">23863060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization, “Vincristine (and Other Vinca Alkaloids) Should Only Be Given Intravenously via a Minibag,” Alert 115, July 2007, World Health Organization, Geneva. Available at http://www.who.int/medicines/publications/drugalerts/Alert_115_vincristine.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35948477">
<a name="35948477"></a>Yasuda H, Komatsu N, Ando J, Ando M. Hodgkin lymphoma on hemodialysis: a review of treatment and recommendations. <i>Clin Lymphoma Myeloma Leuk</i>. 2022;22(11):805-811. doi:10.1016/j.clml.2022.07.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/35948477/pubmed" id="35948477" target="_blank">35948477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33938097">
<a name="33938097"></a>Yasuda H, Yasuda M, Komatsu N. Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review. <i>Cancer Sci</i>. 2021;112(7):2607-2624. doi:10.1111/cas.14933<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/33938097/pubmed" id="33938097" target="_blank">33938097</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12882 Version 292.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
